BMJ· 2026Q1
Early national comparison of robotic versus conventional hip replacements for arthritis using National Joint Registry data: target trial emulation study
- 1citations
- Q1SCImago
- 2026year
Short summary
Robotic total hip replacement (THR) showed no difference in overall implant survival (98.8%) or patient survival (96.2%) compared to conventional THR over five years, but was associated with a significantly lower risk of revisions due to implant malpositioning (HR 0.53, P=0.03).
AI-generated from the title and abstract; the full text is not read.
Key points
- Five-year implant survival was 98.8% for both robotic and conventional total hip replacements (THRs).
- Patient survival at five years was 96.3% for conventional THR and 96.2% for robotic THR.
- Robotic THR demonstrated a significantly lower risk of revisions related to implant malpositioning (HR 0.53, P=0.03).
- No differences were observed in overall revision risk, cause-specific revision risk, or intraoperative complications.
AI-generated from the title and abstract; the full text is not read.
Abstract
OBJECTIVES: To evaluate the early comparative effectiveness of robotic versus conventional total hip replacement (THR) in the UK. DESIGN: Target trial emulation study. SETTING: Public and private hospitals using data from the National Joint Registry of England, Wales, Northern Ireland, the Isle of Man, Guernsey, and Jersey. PARTICIPANTS: 666 283 THRs performed between 2018 and 2024; 656 080 were conventional THRs and 10 203 were robotic THRs. MAIN OUTCOME MEASURES: Five year THR implant survival (mean 2.5 year follow-up), all cause revision risk, cause specific revision risk, malpositioning revision risk, intraoperative complications, and patient survival up to five years. Kaplan-Meier survival analysis, Cox proportional hazards regression, and Fine and Gray models were used. Propensity score matching created comparable treatment groups to estimate the average treatment effect in the treated population. RESULTS: The five year implant survival of the matched conventional and robotic THR groups was 98.8% (95% confidence interval (CI) 98.6% to 99.0%) and 98.8% (CI 98.3% to 99.1%), respectively, with no difference in revision risk between groups (hazard ratio 0.96, 95% CI 0.75 to 1.22; P=0.73). Cause specific revision risk and intraoperative complication risks did not differ between groups. However, a significantly lower risk of revisions related to implant malposition (dislocation, leg length discrepancy, and malalignment) was observed in the robotic group (hazard ratio 0.53, 95% CI 0.30 to 0.93; P=0.03). The five year patient survival of the matched conventional and robotic THR groups was 96.3% (95% CI 95.8% to 96.8%) and 96.2% (95.2% to 97.0%), respectively, with no difference in all cause mortality risk (hazard ratio 1.12, 95% CI 0.95 to 1.34; P=0.17). CONCLUSIONS: No significant differences were found in overall THR or patient survival, cause specific revision, or intraoperative complication risks between robotic and conventional groups. Robotic THR was associated with a lower revision risk from causes related to implant malpositioning. However, the possibility of unmeasured and residual confounding cannot be ruled out owing to the observational design. These results highlight the importance of careful evaluation of robotic technology in publicly funded healthcare systems because of the substantially higher capital and procedural costs.
The authors' abstract, as published at the source. BMJ, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Surgery
SurgeryMedicine